Murphy Matthew B.'s Form 4 filing
Nautilus Biotechnology, Inc. (NAUT) · filed Aug 16, 2022
- Accession no.
- 0001808805-22-000093
- Filed
- Aug 16, 2022
- Trade date
- Aug 12-15, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $28.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Murphy Matthew B.CIK 0001865778 | Officer (General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2022 | Common Stock | PPurchaseAcquired | +2,500 | $2.85 | +$7,125 | 46,640 | Indirect | |
| Aug 15, 2022 | Common Stock | PPurchaseAcquired | +7,500 | $2.84 | +$21,300 | 54,140 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.